VIDEO: New data on allogeneic CAR T-cells
In this video, Joshua Sasine, MD, PhD, assistant professor of medicine hematology and cellular therapy at Samuel Oschin Cancer Center Regenerative Medicine Institute, discusses new allogeneic chimeric antigen receptor T-cell therapy data.
The important data, which was presented at ASH, came in terms of the durability of the allogeneic CAR T cells, which Sasine said did not seem to be as durable as autologous CAR T cells.
"I think this might change the way we use these in the real-world setting, perhaps using them after auto CAR-T or in those patients who have auto CAR-T manufacturing failure or those who have aggressive disease," he said.
Collapse
Locke F, et al. Abstract 2. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Kamdar M, et al. Abstract 91. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.